A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This study is a phase I/II open-label study in patients with relapsed indolent NHL (Part A)
or relapsed/refractory FL (Part B). Part A of the study assessed the safety and preliminary
efficacy. This seamless design study now has four parts: 1) Part A, Ph I - dose escalation,
2) Part A, Ph II - dose expansion, 3) Part B, Ph II randomized - refinement of dose, and 4)
Part B, Phase II, single-arm. As of August 7, 2020, patients are enrolling in the fourth part
of the study.